This could provide a hint that alternative NF-κB activation stimulates altered intracellular and paracrine signaling from tumor cells, since RelA-P50 and RelB-P100/P52 complexes bind to NF-κB binding sites of different promoters [33]. The gene discussed is CD40; the disease is neoplasm.